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Report of an abscopal effect induced by
stereotactic body radiotherapy and
nivolumab in a patient with metastatic
non-small cell lung cancer
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Abstract
Background: The existence of abscopal effects has been suggested already a long time ago, but only recently with
the advent of immune checkpoint inhibition in clinical oncology and modern imaging techniques has it become
possible to directly observe such effects in patients. They have been well described in patients with malignant
melanoma being treated with immune-checkpoint inhibitors and stereotactic radiotherapy, but experience in other
malignancies is very limited.
Case presentation: Here, we describe a case of a patient with metastatic non-small cell lung cancer, who
experienced a complete response secondary to an abscopal effect on treatment with anti-PD-1 therapy and
stereotactic body radiotherapy to some of the involved sites.
Conclusions: Our case reports confirms the existence of abscopal effects in NSCLC and suggests synergism
between immune-checkpoint inhibition and local ablative RT. We suggest that this approach is now further
studied in prospective clinical trials on oligo-metastatic or oligo-progressing NSCLC.
Keywords: Anti-PD-1 therapy, Nivolumab, Immune-checkpoint inhibition, Abscopal effect, Stereotactic body
radiotherapy, Non-small cell lung cancer
Background
Mole introduced the term ‘abscopal effect’ in 1953 [1]. It
describes a phenomenon characterized by tumor regression
of untreated metastatic lesions after a local treatment, such
as radiotherapy. This is thought to arise because ionizing
irradiation causes localized cell death, which induces an
immune response called immunogenic cell death. This is
triggered by increased antigen release, by improved antigen
presentation through increased expression of MHC I on
the tumor cell surface, as well as by modulation of
cytokines enhancing migration and function of effector
CD8+ T cells [2]. However, this event is rare due to
immunotolerance at the tumor site, leading to a reduced
systemic immune response. Treatment with immune
checkpoint inhibitors might overcome tumor-related
immunosuppression and start, as well as sustain the
immune response towards cancer [3, 4].
Case presentation
We report on a 47-year-old male current smoker (40
PY), who was diagnosed with lung adenocarcinoma
(cT1a pN3 cM0, UICC Stage IIIB). He underwent com-
bination treatment with chemotherapy and cetuximab,
followed by radio-therapy in combination with cetuximab
and surgical resection as part of a clinical trial (SAKK 16/08;
NCT01059188). A pathologically complete response was
achieved, but only 8 weeks post-operatively, retroperitoneal
lymph node relapse occurred. Since sensitizing mutations
were absent, we started palliative chemotherapy (cisplatin /
pemetrexed, followed by pemetrexed maintenance).
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However, maintenance pemetrexed had to be discontinued
after two cycles due to severe hematological side effects
CTCAE grade 3, requiring in-patient treatment over several
days.
After full recovery, a PET/CT scan performed four
weeks after hospital demission revealed progressing
abdominal lymph nodes (Fig. 1a). The patient was
enrolled into an expanded access program (EAP) of the
anti-programmed death 1 (PD-1) monoclonal antibody
nivolumab. A first PET/CT scan after 6 cycles (i.e. 13 weeks
after administration of the first nivolumab dose) showed a
mixed response. The initially progressing sites were regres-
sing, but three new abdominal lymph node metastases
appeared (Fig. 1b).
The patient was treated with stereotactic body radiother-
apy (SBRT) for this oligo-progression (Fig. 2a and b). Two
out of the three lymph node metastases were irradiated
(3 × 6 Gy = 18 Gy at 80% isodose) (Figs. 1b and 2b). The
third lymph node remained un-irradiated because of close
proximity to the small bowel and as reference lesion for
immunotherapy. It received a radiation scatter dose of
0.4 Gy only, which is far below clinically significant
anti-tumor doses. The patient continued treatment with
nivolumab during SBRT and thereafter. A PET/CT scan
10 weeks after SBRT (after 13 nivolumab applications in
total), showed a complete radiological and metabolic
response (CR). Importantly, also the third lymph node
metastasis, which had previously progressed and was not
irradiated, showed a CR (Fig. 1c). Such a response after
initial progression in the absence of any local treatment
represents an abscopal effect provoked by PD-1 targeting
in combination with SBRT.
During cycle 17, a severe pancreatitis CTCAE Grade 3
occurred and the patient had to be treated for several
days as an in-patient, but eventually recovered fully. In
the absence of other provoking factors, the most likely
differential diagnosis was immune-related pancreatitis
and nivolumab was therefore permanently stopped. The
patient is today, almost two years after permanently
stopping nivolumab, still in complete remission and in
regular follow-up in our department (Fig. 1d).
Discussion and conclusions
Here we describe a case of a patient with metastatic
NSCLC experiencing a complete response on treatment
with anti-PD-1 therapy and SBRT. A biopsy of the
non-irradiated lesion before SBRT was not clinically
feasible. Therefore, we cannot principally rule out alter-
native explanations, such as for example a delayed response
to immune checkpoint inhibition. However, the temporal
course is highly suggestive of a true abscopal effect.
The existence of abscopal effects has been suggested
already several decades ago, but only with the advent of
immune-checkpoint inhibitors in clinical routine has it
become possible to observe those effects directly in
patients. There are several case reports and retrospective
analyses suggesting that combining immune-checkpoint
inhibition with SBRT might be beneficial in patients with
Fig. 1 a PET/CT staging before start of treatment with nivolumab: the red arrows indicate the localization of the lymph node metastases. b PET/CT
re-staging after 6 cycles of nivolumab with evidence of complete response of the previous metastases and appearance of new metastases, indicated
by yellow arrows. Two out of the three new metastases were irradiated, as indicated. c PET/CT restaging 10 weeks after radiotherapy with evidence of
complete response. d PET/CT restaging two years after start of nivolumab confirming a stable complete remission
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malignant melanoma [5, 6]. In a first report of 101
patients treated with the anti-CTLA4 immune-checkpoint
inhibitor ipilimumab, 70 received radiotherapy at some
point during their treatment and 31 did not. The median
overall survival (OS) in a retrospective analysis was
significantly increased in the group, which received RT
(19 months vs. 10 months for ipilimumab alone [p = 0.01])
[5]. A similar observation was made in a second analysis
studying specifically patients who received anti-PD-1
immune-checkpoint inhibition and radiotherapy. Of 59
patients who received pembrolizumab (n = 28) or nivolumab
(n= 31), 17 also received palliative RT. The combination
was not associated with increased toxicity and the objective
response rate (complete or partial response) was significantly
higher in the group, which had received RT (64.7 vs.
33.3%, P = 0.02), including one complete responder
who exhibited a classical abscopal effect. Such abscopal
effects might be especially triggered by RT when limited
to the involved region, as showed in preclinical models,
in which spearing of draining lymph nodes is crucial
to develop antitumor responses [7]. Taken together,
these observations indicate that combining RT with
immune-checkpoint inhibition (either targeting CTLA4
or PD-1) is well tolerated and has therapeutic potential in
malignant melanoma.
Experience in other solid malignancies is more limited,
given that immune-checkpoint inhibition first entered
clinical routine in melanoma. There are some indications
that abscopal effects also exist in NSCLC. A case report
described a spontaneous regression of a second pulmon-
ary lesion after having applied SBRT to a first lesion only
[8], and there is also a report of an abscopal effect in a
patient with adenocarcinoma of the lung receiving a
combination of anti-CTLA4 inhibition (using ipilimumab)
and SBRT [9]. Moreover, there is evidence from the
randomized phase III trial PACIFIC that consolidation
immune-checkpoint inhibition using durvalumab after
concurrent, definite radio-chemotherapy is beneficial in
patients with stage III NSCLC [10].
Our observation in this case now suggests a synergy of
concurrent immune-checkpoint inhibition targeting the
PD-1/PD-L1 axis and local ablative radiotherapy in
NSCLC, as well. This approach should now be studied
further in prospective clinical trials in the context of
oligo-progressing and oligo-metastatic NSCLC.
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Fig. 2 a Coronal image of the dose distribution of radiotherapy. The patient received 3 × 6 Gy @ 80%. b Image fusion of FDG-PET and treatment
plan showing 30% of the prescribed dose (blue) in relation to the untreated FDG-positive lymph node (indicated by the yellow arrow)
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